Consuelo Buttigliero

Author

Also Known As

C Buttigliero, C. Buttigliero, C. buttigliero, Consuelo BUTTIGLIERO, Consuelo ButtIgliero, Consuelo Buttigliero, Michela Buglione, Sebastiano Buti

147

Publications

Citations

H-Index

Concepts

All Affiliations

University of Turin Ospedale San Luigi Gonzaga Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto Ospedale Santa Chiara

About

Consuelo Buttigliero is an author at University of Turin specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	808
2	Health Sciences	3	3	136
3	Pathology	2	2	77
4	Endocrinology	1	1	63
5	Immunology	1	1	61

Consuelo Buttigliero

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyCancer Treatment	2021	269
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study Cristina Masini, Cinzia Iotti, Ugo De Giorgi, European Urology Pretreated PatientsUrologyRadiation MedicineRadiation TherapyGenitourinary Cancer	2021	99
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) Silke Gillessen, Fabio Turco, Ian D. Davis, European Urology	2024	87
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study Orazio Caffo, Ugo De Giorgi, Lucia Fratino, European Urology Italian Multicentre StudyUrologyGenitourinary CancerMedicineOther Second-line Treatment	2014	83
Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer Valentina Bertaglia, Marcello Tucci, Cristian Fiori, Clinical Genitourinary Cancer AndrologyUrologyAndrogen Deprivation TherapyProstatic DiseaseEndocrinology	2013	63
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma Namrata S. Patil, Luisella Righi, Hartmut Koeppen, Journal of Thoracic Oncology Tumor Immune MicroenvironmentMalignant Pleural MesotheliomaCancer ImmunosurveillanceImmunologyTumor Immunity	2017	61
Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases Eleonora Duregon, Marco Volante, Enrico Bollito, Human Pathology Adrenal GlandRadiologySurgical PathologyAdrenal DiseaseMedicine	2015	54
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort Giuseppe Fornarini, Sara Elena Rebuzzi, Giuseppe Luigi Banna, ESMO Open	2021	54
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation Gian Marco Franceschini, Orsetta Quaini, Kei Mizuno, Cancer Discovery	2023	54

Page 1